checkAd

    Amyris - von 500 auf 2,50 Dollar und jetzt wieder zurück? (Seite 35)

    eröffnet am 22.08.17 12:11:52 von
    neuester Beitrag 12.09.23 08:49:18 von
    Beiträge: 472
    ID: 1.259.956
    Aufrufe heute: 0
    Gesamt: 48.016
    Aktive User: 0

    ISIN: US03236M2008 · WKN: A2DS41 · Symbol: AMRSQ
    0,0020
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 08.05.24 Nasdaq OTC

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    9,4490+125,06
    17,495+45,07
    1,3300+30,51
    1,9700+27,10
    1,9800+26,11
    WertpapierKursPerf. %
    0,7200-18,18
    5,7500-18,44
    1,7490-19,62
    2,8800-28,71
    3,5200-74,14

    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 35
    • 48

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 19.02.20 14:44:48
      Beitrag Nr. 132 ()
      Amyris | 3,145 €
      Avatar
      schrieb am 06.02.20 11:59:49
      Beitrag Nr. 131 ()
      So könnte jetzt endlich mal gut werden 😉

      Hat hier noch jemand Durchgehalten?


      Amyris Announces Execution of Definitive Agreements for up to an Anticipated $70 Million Debt Reduction Via Exercise of Existing Warrants and $42 Million in New Financing https://seekingalpha.com/pr/17766731?source=ansh $AMRS
      Amyris | 3,025 €
      Avatar
      schrieb am 08.11.19 16:05:42
      Beitrag Nr. 130 ()
      Amyris Continues to Deliver Strong Revenue Growth https://seekingalpha.com/pr/17692113?source=ansh $AMRS

      Amyris, Inc. 2019 Q3 - Results - Earnings Call Presentation https://seekingalpha.com/article/4304133?source=ansh $AMRS


      Amyris' (AMRS) CEO John Melo on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4304131?source=ansh $AMRS
      Amyris | 4,220 $
      Avatar
      schrieb am 23.10.19 19:09:38
      Beitrag Nr. 129 ()
      Amyris, Inc.: A Sweet Future Brought To You By John Doerr https://seekingalpha.com/article/4298152?source=ansh $AMRS
      Amyris | 3,700 $
      Avatar
      schrieb am 09.10.19 14:28:05
      Beitrag Nr. 128 ()
      https://seekingalpha.com/article/4295691-amyris-life-support…

      Was der Doerr mit der filletierten Amyris anfangen will erschließt sich mir auch nicht....in der Firma ist kaum noch etwas was eine derart hohe Kapitalisierung rechtfertigt...:rolleyes:
      Amyris | 3,656 €

      Trading Spotlight

      Anzeige
      InnoCan Pharma
      0,2130EUR +1,43 %
      Unfassbare Studie – LPT-Therapie bewahrt Patient vor dem Tod!mehr zur Aktie »
      Avatar
      schrieb am 07.10.19 13:12:29
      Beitrag Nr. 127 ()
      On September 16, 2019, the Company failed to pay an aggregate of $63.6 million of outstanding principal and accrued interest on the Second Exchange Note when due. The failure resulted in an event of default under the Second Exchange Note and also triggered cross-defaults under other debt instruments of the Company which permitted the holders of such indebtedness to accelerate the amounts owing under such instruments. The Company subsequently received waivers from substantially all holders of such other debt instruments to waive the right to accelerate. As a result, the indebtedness with respect to which the Company has obtained such waivers continues to be classified as long-term on the Company’s balance sheet. The indebtedness reflected by the Second Exchange Note continues to be classified as a current liability on the Company’s balance sheet. In addition, as a result of the payment default, the conversion price of the Second Exchange Note is subject to adjustment in accordance with the terms of the Second Exchange Note.


      The Company does not currently have sufficient funds to repay the amounts outstanding under the Second Exchange Note. To date, negotiations with the holder of the Second Exchange Note have not been successful, and there can be no assurance that a favorable outcome for the Company will be reached. The Company has executed a term sheet with an existing investor for a term loan, the proceeds of which would be used to repay a portion of the Second Exchange Note. However, there can be no assurance that the Company will be able to obtain such financing on its expected timeline, or on acceptable terms, if at all. Even if the Company does obtain such financing, it will not have sufficient funds to repay the Second Exchange Note in full without obtaining additional financing, which the Company is attempting to source. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

      https://www.sec.gov/Archives/edgar/data/1365916/000117184319… (Seite 11)

      Upsi - kleine Kettenreaktion - mal sehen was sie jetzt aus dem Zylinder zaubern :rolleyes:
      Amyris | 3,919 €
      Avatar
      schrieb am 01.10.19 15:38:30
      Beitrag Nr. 126 ()
      Amyris | 4,278 €
      Avatar
      schrieb am 10.09.19 22:39:36
      Beitrag Nr. 125 ()
      http://wsw.com/webcast/hcw5/amrs/index.aspx

      Also Laut Ceo schafft es Amyris bis Ende September tatsächlich die 10k und 10q zu liefern.

      Operativ scheint alles gut zu laufen. Ich hoffe dass es dieses Mal mehr als nur versprechen sind.
      Ich bin allerdings recht optimistisch.
      Amyris | 4,144 €
      Avatar
      schrieb am 13.08.19 22:54:03
      Beitrag Nr. 124 ()
      Man muss hier schon echt Nerven haben...🤪

      Pricing Amyris Into 2020 https://seekingalpha.com/article/4283452?source=ansh $AMRS, $ACB, $BYND, $GWPH, $JNJ, $TWST
      Amyris | 3,459 €
      Avatar
      schrieb am 13.08.19 10:02:44
      Beitrag Nr. 123 ()
      Bestimmt demnächst dann wieder durch irgendwas -30% oder so. Was für ne Aktie. 😂
      Amyris | 3,492 €
      • 1
      • 35
      • 48
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      -0,90
      -0,50
      -2,36
      -5,38
      -3,78
      +0,37
      -0,73
      +0,41
      -3,83
      -3,63

      Meistdiskutiert

      WertpapierBeiträge
      175
      127
      101
      79
      72
      50
      45
      42
      39
      36
      Amyris - von 500 auf 2,50 Dollar und jetzt wieder zurück?